Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283720791> ?p ?o ?g. }
- W4283720791 endingPage "793" @default.
- W4283720791 startingPage "783" @default.
- W4283720791 abstract "Summary Background During illness, adaptations of the hypothalamic–pituitary‐thyroid axis reduce energy expenditure, protein catabolism and modulate immune responses to promote survival. Lower serum free triiodothyronine‐to‐thyroxine (fT3/fT4) ratio has been linked to non‐response to treatment in a range of diseases, including in biologic‐treated patients with inflammatory bowel disease. Aim To assess whether baseline serum fT3/fT4 ratio predicted primary non‐response (PNR) and non‐remission to infliximab and adalimumab in patients with Crohn's disease Methods Thyroid function tests were undertaken in stored serum from biologic‐naïve adult patients with active luminal Crohn's disease immediately prior to treatment with infliximab (427 originator; 122 biosimilar) or adalimumab (448) in the Personalised Anti‐TNF Therapy in Crohn's Disease study (PANTS). Results Baseline median [IQR] fT3/fT4 ratios were lower in women than men (0.30 [0.27–0.34] vs 0.32 [0.28–0.36], p < 0.001), in patients with more severe inflammatory disease, and in patients receiving corticosteroids (0.28 [0.25–0.33] vs. 0.32 [0.29–0.36], p < 0.001). Multivariable logistic regression analysis demonstrated that fT3/fT4 ratio was independently associated with PNR at week 14 (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.31–0.85, p = 0.009), but not non‐remission or changes in faecal calprotectin concentrations at week 54. The optimal threshold to determine PNR was 0.31 (area under the curve 0.57 [95% CI 0.54–0.61], sensitivity 0.62 [95% CI 0.41–0.74], and specificity 0.53 [95% CI 0.42–0.73]). Conclusions Lower baseline serum fT3/fT4 ratio was associated with female sex, corticosteroid use and disease activity. It predicted PNR to anti‐TNF treatment at week 14, but not non‐remission at week 54." @default.
- W4283720791 created "2022-07-01" @default.
- W4283720791 creator A5010298107 @default.
- W4283720791 creator A5010484965 @default.
- W4283720791 creator A5024002886 @default.
- W4283720791 creator A5032264449 @default.
- W4283720791 creator A5045735248 @default.
- W4283720791 creator A5048734090 @default.
- W4283720791 creator A5054271143 @default.
- W4283720791 creator A5069067500 @default.
- W4283720791 creator A5069238850 @default.
- W4283720791 creator A5076631930 @default.
- W4283720791 creator A5082782814 @default.
- W4283720791 date "2022-06-29" @default.
- W4283720791 modified "2023-09-27" @default.
- W4283720791 title "Understanding <scp>anti‐TNF</scp> treatment failure: does serum triiodothyronine‐to‐thyroxine ( <scp>T3</scp> / <scp>T4</scp> ) ratio predict therapeutic outcome to <scp>anti‐TNF</scp> therapies in biologic‐naïve patients with active luminal Crohn's disease?" @default.
- W4283720791 cites W1541671351 @default.
- W4283720791 cites W1995768930 @default.
- W4283720791 cites W2008114180 @default.
- W4283720791 cites W2022661087 @default.
- W4283720791 cites W2025402613 @default.
- W4283720791 cites W2035599521 @default.
- W4283720791 cites W2058696406 @default.
- W4283720791 cites W2065558920 @default.
- W4283720791 cites W2082935047 @default.
- W4283720791 cites W2092190921 @default.
- W4283720791 cites W2152575748 @default.
- W4283720791 cites W2168760648 @default.
- W4283720791 cites W2188248802 @default.
- W4283720791 cites W2291058351 @default.
- W4283720791 cites W2521998148 @default.
- W4283720791 cites W2537831565 @default.
- W4283720791 cites W2552690718 @default.
- W4283720791 cites W2604780989 @default.
- W4283720791 cites W2784524664 @default.
- W4283720791 cites W2888647197 @default.
- W4283720791 cites W2912129903 @default.
- W4283720791 cites W2916794721 @default.
- W4283720791 cites W2958721929 @default.
- W4283720791 cites W2978880955 @default.
- W4283720791 cites W3037456164 @default.
- W4283720791 cites W3104241436 @default.
- W4283720791 cites W3112055569 @default.
- W4283720791 cites W3115412531 @default.
- W4283720791 cites W3119363176 @default.
- W4283720791 cites W3180997115 @default.
- W4283720791 cites W4206924240 @default.
- W4283720791 cites W4283720791 @default.
- W4283720791 doi "https://doi.org/10.1111/apt.17089" @default.
- W4283720791 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35768996" @default.
- W4283720791 hasPublicationYear "2022" @default.
- W4283720791 type Work @default.
- W4283720791 citedByCount "4" @default.
- W4283720791 countsByYear W42837207912022 @default.
- W4283720791 countsByYear W42837207912023 @default.
- W4283720791 crossrefType "journal-article" @default.
- W4283720791 hasAuthorship W4283720791A5010298107 @default.
- W4283720791 hasAuthorship W4283720791A5010484965 @default.
- W4283720791 hasAuthorship W4283720791A5024002886 @default.
- W4283720791 hasAuthorship W4283720791A5032264449 @default.
- W4283720791 hasAuthorship W4283720791A5045735248 @default.
- W4283720791 hasAuthorship W4283720791A5048734090 @default.
- W4283720791 hasAuthorship W4283720791A5054271143 @default.
- W4283720791 hasAuthorship W4283720791A5069067500 @default.
- W4283720791 hasAuthorship W4283720791A5069238850 @default.
- W4283720791 hasAuthorship W4283720791A5076631930 @default.
- W4283720791 hasAuthorship W4283720791A5082782814 @default.
- W4283720791 hasBestOaLocation W42837207911 @default.
- W4283720791 hasConcept C126322002 @default.
- W4283720791 hasConcept C134018914 @default.
- W4283720791 hasConcept C156957248 @default.
- W4283720791 hasConcept C2777138892 @default.
- W4283720791 hasConcept C2778288131 @default.
- W4283720791 hasConcept C2779134260 @default.
- W4283720791 hasConcept C2780132546 @default.
- W4283720791 hasConcept C44249647 @default.
- W4283720791 hasConcept C526584372 @default.
- W4283720791 hasConcept C71924100 @default.
- W4283720791 hasConcept C90924648 @default.
- W4283720791 hasConceptScore W4283720791C126322002 @default.
- W4283720791 hasConceptScore W4283720791C134018914 @default.
- W4283720791 hasConceptScore W4283720791C156957248 @default.
- W4283720791 hasConceptScore W4283720791C2777138892 @default.
- W4283720791 hasConceptScore W4283720791C2778288131 @default.
- W4283720791 hasConceptScore W4283720791C2779134260 @default.
- W4283720791 hasConceptScore W4283720791C2780132546 @default.
- W4283720791 hasConceptScore W4283720791C44249647 @default.
- W4283720791 hasConceptScore W4283720791C526584372 @default.
- W4283720791 hasConceptScore W4283720791C71924100 @default.
- W4283720791 hasConceptScore W4283720791C90924648 @default.
- W4283720791 hasFunder F4320307765 @default.
- W4283720791 hasFunder F4320309088 @default.
- W4283720791 hasFunder F4320309117 @default.
- W4283720791 hasFunder F4320312327 @default.
- W4283720791 hasFunder F4320321982 @default.
- W4283720791 hasFunder F4320332932 @default.
- W4283720791 hasIssue "5" @default.
- W4283720791 hasLocation W42837207911 @default.